Igor Pagiola1, Cristian Mihalea2, Jildaz Caroff2, Leon Ikka2, Vanessa Chalumeau2, Marta Iacobucci2, Augustin Ozanne2, Sophie Gallas2, Marcio Marques3, Darcio Nalli3, Henrique Carrete3, José Guilherme Caldas4, Michel Eli Frudit3, Jacques Moret2, Laurent Spelle2. 1. Department of Interventional Neuroradiology Neuro Brain Vascular Center, Hôpital Bicêtre, Paris Sud Université, AP-HP, 78 Rue du Général Leclerc, 94270 Le Kremlin-Bicêtre, France; Department of Interventional Neuroradiology, Universidade Federal de São Paulo, São Paulo SP, Brazil. Electronic address: igorpagiola@hotmail.com. 2. Department of Interventional Neuroradiology Neuro Brain Vascular Center, Hôpital Bicêtre, Paris Sud Université, AP-HP, 78 Rue du Général Leclerc, 94270 Le Kremlin-Bicêtre, France. 3. Department of Interventional Neuroradiology, Universidade Federal de São Paulo, São Paulo SP, Brazil. 4. Department of Interventional Neuroradiology, Universidade de São Paulo, São Paulo SP, Brazil.
Abstract
BACKGROUND AND PURPOSE: The PHASES score was formulated to predict the 5-year risk of rupture for intracranial aneurysms. We retrospectively analyzed all patients treated in our institution for aneurysmal SAH and applied the PHASES score to estimate the probable predicted risk of bleeding in this group of patients. METHODS: Between February 2015 and August 2018, all patients with aneurysmal SAH were retrospectively analyzed and the PHASES score was applied. A total of 155 patients were included with a mean age of 53.8years, including 60 males and 95 females. RESULTS: Of our patients 110 (70.9%) had a PHASES score of below or equal to 5, with a hemorrhagic risk of up to 1.3% over 5years. If we analyze the patients with a risk of below 2% this figure increases to 122 patients (78.7%). Of these 99.3% were European and 0.6% were Japanese (1 patient). In 86 patients (55.4%), the aneurysm was smaller than 5mm and in 10 patients (6.4%) the aneurysm was located in the posterior circulation. CONCLUSION: Of our patients 78.7% had less than a 2% 5-year rupture risk based on their PHASES score, highlighting the discrepancy of the rupture risk calculated with the PHASES score when hypothetically applied to this group of patients. In the hypothetical scenario that our patients had unruptured aneurysms, our retrospective analysis shows that the PHASES score may only provide a weak tool for clinicians to use in the decision-making process as to whether or not to treat these aneurysms.
BACKGROUND AND PURPOSE: The PHASES score was formulated to predict the 5-year risk of rupture for intracranial aneurysms. We retrospectively analyzed all patients treated in our institution for aneurysmalSAH and applied the PHASES score to estimate the probable predicted risk of bleeding in this group of patients. METHODS: Between February 2015 and August 2018, all patients with aneurysmalSAH were retrospectively analyzed and the PHASES score was applied. A total of 155 patients were included with a mean age of 53.8years, including 60 males and 95 females. RESULTS: Of our patients 110 (70.9%) had a PHASES score of below or equal to 5, with a hemorrhagic risk of up to 1.3% over 5years. If we analyze the patients with a risk of below 2% this figure increases to 122 patients (78.7%). Of these 99.3% were European and 0.6% were Japanese (1 patient). In 86 patients (55.4%), the aneurysm was smaller than 5mm and in 10 patients (6.4%) the aneurysm was located in the posterior circulation. CONCLUSION: Of our patients 78.7% had less than a 2% 5-year rupture risk based on their PHASES score, highlighting the discrepancy of the rupture risk calculated with the PHASES score when hypothetically applied to this group of patients. In the hypothetical scenario that our patients had unruptured aneurysms, our retrospective analysis shows that the PHASES score may only provide a weak tool for clinicians to use in the decision-making process as to whether or not to treat these aneurysms.
Authors: James Feghali; Abhishek Gami; Risheng Xu; Christopher M Jackson; Rafael J Tamargo; Cameron G McDougall; Judy Huang; Justin M Caplan Journal: Neurosurg Rev Date: 2021-04-02 Impact factor: 3.042
Authors: P Lognon; F Gariel; G Marnat; J Darcourt; P Constant Dit Beaufils; J Burel; E Shotar; J F Hak; C Fauché; B Kerleroux; A Guédon; J Ognard; G Forestier; R Pop; C Paya; J B Veyrières; P Sporns; J B Girot; R Zannoni; F Zhu; A Crespy; V L'Allinec; D Mihoc; A Rouchaud; J C Gentric; W Ben Hassen; N Raynaud; B Testud; F Clarençon; B Kaczmarek; R Bourcier; G Bellanger; G Boulouis; Kevin Janot Journal: Neuroradiology Date: 2022-06-13 Impact factor: 2.804
Authors: Anders Blach Naamansen; Carl Christian Larsen; Bjarni Johannsson; Sune Munthe; Troels Halfeld Nielsen Journal: Surg Neurol Int Date: 2022-07-08
Authors: Jason M Acosta; Anne F Cayron; Nicolas Dupuy; Graziano Pelli; Bernard Foglia; Julien Haemmerli; Eric Allémann; Philippe Bijlenga; Brenda R Kwak; Sandrine Morel Journal: Front Cardiovasc Med Date: 2021-12-08
Authors: Michael Karl Fehrenbach; Eric Dietel; Tim Wende; Johannes Kasper; Caroline Sander; Florian Wilhelmy; Ulf Quaeschling; Juergen Meixensberger; Ulf Nestler Journal: Brain Sci Date: 2022-02-28